{"entity":{"id":"nct04567420","kind":"trial","name":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)","aka":["DARE"],"tldr":"A phase 2 trial of Palbociclib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by Criterium, Inc., active and no longer recruiting.","summary":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) is a phase 2 interventional study registered as NCT04567420 by Criterium, Inc., with 70 participants enrolled, started 2021-02-09 and due to reach its primary completion in 2027-12-31. Interventions recorded: Palbociclib, Fulvestrant and Adjuvant Therapy.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04567420","url":"https://clinicaltrials.gov/study/NCT04567420"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["palbociclib","fulvestrant"],"companies":["criterium"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04567420","phase":"2","setting":"A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)","sponsor":"Criterium, Inc.","participation":[{"nct":"NCT04567420","source":"https://clinicaltrials.gov/study/NCT04567420","fetchedAt":"2026-10-07T16:53:22.534Z","studySha256":"8e7dadf1123e17365b2a76241ae1457c41d7802be6070323f7b47409dc20ce5b","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-10-07","leadSponsor":"Criterium, Inc.","collaboratorCount":0,"sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":70,"enrolmentType":"ESTIMATED","siteCount":19,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2021-02-09","startedType":"actual","enrolled":70,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04567420/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"}],"company":[{"id":"criterium","kind":"company","name":"Criterium","route":"/companies/criterium/"}]}}